Jefferies Group LLC Lowers AcelRx Pharmaceuticals, Inc. (ACRX) to Hold

Jefferies Group LLC lowered shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) from a buy rating to a hold rating in a report issued on Friday, Marketbeat.com reports.

A number of other analysts have also recently weighed in on ACRX. Cowen and Company reaffirmed a hold rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 1st. ValuEngine raised AcelRx Pharmaceuticals from a strong sell rating to a sell rating in a research report on Tuesday, September 26th. Zacks Investment Research raised AcelRx Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, August 4th. Roth Capital set a $8.00 price objective on AcelRx Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, October 12th. Finally, Piper Jaffray Companies set a $3.00 price target on AcelRx Pharmaceuticals and gave the company a hold rating in a report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. AcelRx Pharmaceuticals currently has an average rating of Hold and an average target price of $7.67.

AcelRx Pharmaceuticals (NASDAQ ACRX) opened at 1.95 on Friday. The firm has a 50-day moving average price of $3.80 and a 200-day moving average price of $2.97. The firm’s market capitalization is $88.49 million. AcelRx Pharmaceuticals has a one year low of $1.90 and a one year high of $5.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). The business had revenue of $2.66 million during the quarter, compared to the consensus estimate of $2.63 million. Equities analysts anticipate that AcelRx Pharmaceuticals will post ($1.13) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Jefferies Group LLC Lowers AcelRx Pharmaceuticals, Inc. (ACRX) to Hold” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/10/17/jefferies-group-llc-lowers-acelrx-pharmaceuticals-inc-acrx-to-hold.html.

In other news, CEO Vincent J. Angotti acquired 15,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Thursday, August 24th. The stock was purchased at an average cost of $3.00 per share, with a total value of $45,000.00. Following the completion of the acquisition, the chief executive officer now owns 15,000 shares in the company, valued at approximately $45,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pamela P. Palmer acquired 10,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $29,500.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 37,000 shares of company stock valued at $112,280. 28.10% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in AcelRx Pharmaceuticals by 6.6% during the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after purchasing an additional 6,942 shares during the last quarter. Teachers Advisors LLC increased its position in AcelRx Pharmaceuticals by 14.6% during the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares in the last quarter. WealthTrust Axiom LLC increased its position in AcelRx Pharmaceuticals by 50.0% during the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after buying an additional 70,000 shares in the last quarter. Virtu KCG Holdings LLC increased its position in AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in AcelRx Pharmaceuticals during the second quarter worth $319,000. 23.32% of the stock is owned by hedge funds and other institutional investors.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply